Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Sites in Nebraska: - Ascentage Investigative Site #1097 — Lincoln, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) …
Sponsor: BeOne Medicines
NCT ID: NCT07277231
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 1 Recruiting Industry
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leu…
Sponsor: Umoja Biopharma
NCT ID: NCT06528301
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Recruiting Network
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear …
Sponsor: Children's Oncology Group
NCT ID: NCT05702645
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Recruiting Academic/Other
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05978141
Sites in Nebraska: - University of Nebraska (Data collection only) — Omaha, Nebraska
Recruiting Industry
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Sponsor: Blueprint Medicines Corporation
NCT ID: NCT07143669
Sites in Nebraska: - Somnos Clinical Research — Lincoln, Nebraska
- University of Nebraska — Omaha, Nebraska
Phase 4 Recruiting Industry
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed in…
Sponsor: Eli Lilly and Company
NCT ID: NCT06876649
Sites in Nebraska: - University Of Nebraska Medical Center — Omaha, Nebraska